Novel compounds that modulate cellular metabolism and uses thereof

Abstract

A class of compounds that bind to fatty acid binding protein 4 (FABP4) and regulate adipocyte metabolism to promote enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds in combination with a pharmaceutically acceptable diluent or carrier, optionally further in combination with a therapeutically active agent, and the use of these compounds in the preparation of medicines and medicaments in the treatment of disorders affecting FABP4. JPEG2023518648000225.jpg89103

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 963,508, filed January 20, 2020, the entire contents of which are incorporated herein by reference in their entirety.

[0002] The field of embodiments of the present invention relates to novel compounds for treating or preventing diseases related to metabolism and inflammation, including, but not limited to, type 2 diabetes, atherosclerosis, intracranial atherosclerotic disease, Alzheimer's disease, non-alcoholic steatohepatitis, obesity, cardiovascular disease, asthma, cancer, and other diseases. The compounds of the present invention interact specifically with fatty acid binding protein 4 (FABP4) and improve glucose consumption in adipocytes. [Background technology]

[0003] Fatty acid binding proteins (FABPs) are a family of proteins that reversibly bind free fatty acids and other lipid molecules and facilitate their transport in cells. To date, nine distinct FABP isoforms have been identified in mammals. FABP isoforms exhibit distinct expression patterns in different tissues. Fatty acid binding protein 4 (FABP4), often referred to as aP2 in the literature, is primarily expressed in adipocytes and macrophages and mediates important metabolic and inflammatory pathways in these cells, including lipid storage and degradation, signal transduction, and eicosanoid production. Furthermore, FABP4 is also secreted into plasma and has been proposed to act as an adipose-derived factor regulating whole-body glucose homeostasis.

[0004] Gene knockout studies in mice have provided greater insight into the tissue-specific and systemic functions of FABP4. Importantly, when mice with a homozygous deletion of the FABP4 gene were subjected to a long-term high-fat diet, they gained weight to the same extent as wild-type mice but were protected from hyperglycemia and insulin resistance. See G.S. Hotamisligil, et al., “Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in Ap2, the Adipocyte Fatty Acid Binding Protein,” Science, 1996, 274(5291), Pages 1377–9, doi:10.1126 / science.274.5291.1377. Furthermore, FABP4 deficiency significantly protected apolipoprotein E (ApoE) knockout mice from atherosclerosis, a phenotype resulting from FABP4 regulation of inflammatory pathways in macrophages. See L. Makowski, et al., "Lack of Macrophage Fatty-Acid-Binding Protein aP2 Protects Mice Deficient in Apolipoprotein E Against Atherosclerosis," Nat. Med. 2001, 7(6), Pages 699-705, doi:10.1038 / 89076. FABP4 expression has also been detected in airway epithelial cells, and FABP4 deficiency has been demonstrated to be protective in a mouse model of allergic pulmonary inflammation. See BOV Shum, et al., "The Adipocyte Fatty Acid-Binding Protein aP2 is Required in Allergic Airway Inflammation," J. Clin. Invest., 2006, 116(8), Pages 2183-2192, doi:10.1172 / JCI24767.

[0005] Several reports have been published in the literature linking FABP4 expression levels and function with several human pathologies. For example, a reduced risk of type 2 diabetes and coronary heart disease was observed in individuals with a genetic variant in the promoter region of FABP4 (rs77878271), resulting in reduced expression of this gene. See G. Tuncman, et al., “A Genetic Variant at the Fatty Acid-Binding Protein aP2 Locus Reduces the Risk for Hypertriglyceridemia, Type 2 Diabetes, and Cardiovascular Disease,” Proc. Natl. Acad. Sci. USA, 2006, 103(18), Pages 6970-5, doi:10.1073 / pnas.0602178103. The same polymorphism was also associated with reduced symptoms of atherosclerotic disease in an independent study. See J. Saksi, et al., "Low-Expression Variant of Fatty Acid-Binding Protein 4 Favors Reduced Manifestations of Atherosclerotic Disease and Increased Plaque Stability," Circ. Cardiovasc. Genet., 2014, 7(5), Pages 588-98, doi:10.1161 / CIRCGENETICS.113.000499. Additionally, patients with triple-negative breast cancer harboring a single nucleotide polymorphism in the 3' untranslated region (UTR) of FABP4 (rs1054135-GG genotype), which also results in reduced FAB4 expression, were associated with a reduced risk of disease progression and longer disease-free survival.See W. Wang, et al., “A Single-Nucleotide Polymorphism in the 3'-UTR Region of the Adipocyte Fatty Acid Binding Protein 4 Gene is Associated with Prognosis of Triple-Negative Breast Cancer,” Oncotarget., 2016, 7(14), Pages 18984-18998, doi:10.18632 / oncotarget.7920. Furthermore, increased expression of FABP4 has been observed in the placenta of preeclampsia (a condition characterized by high blood pressure during pregnancy), and it has been proposed to play a role in the pathogenesis of preeclampsia (a condition characterized by high blood pressure during pregnancy). See Y. Yan, et al., "Increased Expression of Fatty Acid Binding Protein 4 in Preeclamptic Placenta and Its Relevance to Preeclampsia," Placenta, 2016, 39, Pages 94-100, https: / / doi.org / 10.1016 / j.placenta.2016.01.014. Similarly, granulosa cells from patients with polycystic ovary syndrome (PCOS) also showed increased FABP4 expression, which correlated with the clinical characteristics of the disease. See W. Hu, et al., "Expression and Regulation of Adipocyte Fatty Acid Binding Protein in Granulosa Cells and Its Relation with Clinical Characteristics of Polycystic Ovary Syndrome," Endocrine, 2011, 40(2), Pages 196-202, doi:10.1007 / s12020-011-9495-9. Collectively, these studies demonstrated the active role of FAPB4 in regulating systemic metabolism and inflammation and suggested that pharmacological targeting of FABP4 could be used as a strategy for treating various diseases related to FABP4 function.

[0006] Adipocytes play a central role in whole-body glucose homeostasis. One of their primary roles is to uptake excess glucose into plasma and store it in the form of lipids. Adipocyte dysfunction due to metabolic stress and inflammation often leads to complications such as hyperglycemia and insulin resistance. It is noteworthy that FABP4-deficient mice exhibited increased glucose deposition in adipose tissue. Adipocytes isolated from these animals showed a significantly elevated rate of glucose conversion to fatty acids compared with wild-type counterparts. See S. Shaughnessy, et al., "Adipocyte Metabolism in Adipocyte Fatty Acid Binding Protein Knockout Mice (Ap2- / -) After Short-Term High-Fat Feeding: Functional Compensation by the Keratinocyte [Correction Of Keritinocyte] Fatty Acid Binding Protein," Diabetes, 2000, 49(6), Pages 904-911, https: / / doi.org / 10.2337 / diabetes.49.6.904. Therefore, increased glucose consumption in adipocytes can be achieved by targeting FABP4.

[0007] Although the literature and certain prior art patent applications (e.g., WO 00 / 47734, WO 00 / 15229, WO 00 / 15230, WO 02 / 40448, WO 01 / 54694, WO 00 / 59506, and WO 2004 / 063156) provide various presentations of the concept of FABP inhibition in general, and FABP4 inhibition in particular, none of the discussions in these prior art documents provides a complete solution to the unmet needs of the present invention. Specifically, the present invention describes a novel class of compounds that bind to FABP4 and regulate adipocyte metabolism to promote enhanced glucose utilization. Summary of the Invention

[0008] In one of its embodiments, the present invention provides a compound of formula (I) [ka] or a pharmaceutically acceptable salt or ester thereof, R 1 and R 6 ~R 9 each independently represents -H, -CN, -COOH, -CONH2, B(OR a )2, Acid Isostere, Halo, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n is heterocycloalkyl, B(OR a )2R a is H or alkyl, B(OR a )2, B is boron, C n n is 1 to 10, R 2 ~R 5 each independently represents -H, -CN, -COOH, -COOMe, -CONH2, B(OR a )2, Acid isostere, Halo, -CONHOH, -NH-SO2-C1~C6-Alkyl, -NHSO2Ar, C n Alkyl, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or Cn is heterocycloalkyl, Ar in -NHSO2Ar is phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, or benzothiophene. selected from the group consisting of phene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene; C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, and C n each heterocycloalkyl is unsubstituted or substituted with 1 to 5 substituents; each substituent is the same or different; Each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl and -Cq -UC q is selected from the group consisting of -C q -UC q Each q is independently 0 to 10; -C q -UC q wherein U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1); Each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n is heterocycloalkyl, Each R1 in N(R1)(R1) is unsubstituted, may be the same or different, and may be H, 2 substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; Q is a bond or O; If X is O or S, then R 6 X is C, N, O or S, so that "A" is [ka] is a saturated or unsaturated ring represented by Y, T, W, and Z are independently a bond, C, N, O, alkyl having 1 to 4 carbon atoms, or alkenyl having 1 to 4 carbon atoms; n is 0, 1, 2, or 3.

[0009] In one embodiment, the present invention provides a compound comprising R 1 and R 2 , R 2 and R 3 , R 3 and R 4 , R 4 and R 5 , R 6 and R 7 , R 7 and R 8 , R 8 and R 9 wherein at least one of is linked to form a fused heteroaryl or a fused heterocycloalkyl.

[0010] In a further embodiment, the present invention provides a compound of formula (II) [ka] or a pharmaceutically acceptable salt or ester thereof, R 1 and R 6 ~R 9 are independently -H, -CN, -COOH, -CONH2, B(OR a )2, Acid Isostere, Halo, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n is heterocycloalkyl, B(OR a )2R a is H or alkyl, B(ORa )2, B is boron, C n n is 1 to 10, R 2 ~R 5 each independently represents -H, -CN, -COOH, -COOMe, -CONH2, B(OR a )2, Acid isostere, Halo, -CONHOH, -NH-SO2-C1~C6-Alkyl, -NHSO2Ar, C n Alkyl, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n is heterocycloalkyl, Ar in -NHSO2Ar is phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, or benzothiophene. selected from the group consisting of phene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene; C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C nHaloalkyl, C n Heteroaryl, C n Cycloalkyl, or C n each heterocycloalkyl is unsubstituted or substituted with 1 to 5 substituents; each substituent is the same or different; Each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl and -C q -UC q is selected from the group consisting of -C q -UC q Each q is independently 0 to 10; -C q -UC q wherein U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1); Each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n is heterocycloalkyl, Each R1 in N(R1)(R1) is unsubstituted, may be the same or different, and may be H, 2substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; Q is a bond or O; If X is O or S, then R 6 X is C, N, O or S, so that X is C, N, O or S; n is 0, 1, 2, or 3.

[0011] In some embodiments, the present invention includes compounds of Formula II, wherein the heterocycloalkyl group is R 7 , R 8 or R 9 Combine two of them [ka] It is formed by forming

[0012] A further embodiment of the present invention is a compound of formula III [ka] or a pharmaceutically acceptable salt or ester thereof, R 1 is -CN, alkyl, -H, halo, 2selected from the group consisting of H, amino, alkoxy, aminoalkyl, (amino)alkoxy, alkenyl, alkynyl, alkoxy, hydroxy, alkylhydroxy, aryloxy, alkyl(aryl), (alkoxyalkyl)amino, aryl, aryl(halo), heteroaryl, hydroxyl-alkyl, hydroxyl-aryl, (aryl)alkyl, C(O)OH, —S(O)2-alkyl, —S(O)2-aryl, —C(O)alkyl, and C(O)NH2; R 3 and R 4 each independently represents -H, halo, C n Alkyl, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, C n Heterocycloalkyl and -C q -UC q and C n n is 1 to 10, -C q -UC q Each q is independently 0 to 10; -C q -UC q U is any one of O, S, SO2, or N(R1)(R1), each R in N(R)(R) is independently hydrogen; C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, and C n each heterocycloalkyl is unsubstituted or substituted with 1 to 5 substituents; each substituent is the same or different; Each substituent is H, 2 selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 6 are independently H or alkyl; R 7 and R 8 each independently represents hydrogen, 2 H, fluoro or alkyl; R 6 and R 7 combines with an adjacent R group to form a fused group, the fused group is selected from the group consisting of fused cycloalkyl, fused heterocycloalkyl, fused aryl, and fused heteroaryl rings; The fused group contains 4 to 10 carbon atoms, n in formula III is 0 or 1; Q is a bond or O; If X is O or S, then R 6 X is C, N, O or S, so that Z 1 or W 1 is independently C, N, O or S.

[0013] Another embodiment of the present invention includes compounds of Formula III where X is N.

[0014] An embodiment of the present invention is 6 is hydrogen and X is N.

[0015] A further embodiment of the present invention is 3is alkyl, and R 1 Includes compounds of formula III where is cyano.

[0016] A further embodiment of the present invention includes compounds of formula III where X is N and n=0.

[0017] An embodiment of the present invention includes compounds of formula III where X is N and n=1.

[0018] Generally, the present invention succeeds in providing the following advantages and objectives:

[0019] It is an object of the present invention to utilize compounds according to Formula (I), (II) or (III) or pharmaceutically acceptable salts or esters thereof to treat disorders affecting fatty acid binding protein 4 (FABP4).

[0020] It is an object of the present invention to provide a pharmaceutical composition comprising as an active ingredient a compound according to Formula (I), (II) or (III) in combination with a pharmaceutically acceptable diluent or carrier for use in the treatment of disorders affecting FABP4, wherein the pharmaceutical composition may further comprise an additional therapeutically active agent.

[0021] The object of the present invention is to provide a method for treating disorders that affect FABP4. Such method comprises a number of process steps, such as administering an effective amount of a compound according to formula (I), (II) or (III) to a subject (preferably human) that requires such treatment. This method optionally comprises a process step of co-administration with other therapeutic agents, either simultaneously or sequentially, as a single (or multiple) administration.

[0022] It is an object of the present invention to provide a method for inhibiting FABP4, comprising the process step of administering to a subject (preferably a human) in need of such treatment an effective amount of a compound according to formula (I), (II) or (III).

[0023] An object of the present invention is to provide a method of using a compound according to Formula (I), (II), or (III) for the manufacture of a medicament for use in treating disorders affecting FABP4. Examples of such disorders include type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, intracranial atherosclerotic disease, nonalcoholic steatohepatitis, asthma, multiple sclerosis, Alzheimer's disease, other chronic inflammatory and autoimmune / inflammatory diseases, chronic heart disease, polycystic ovary syndrome, preeclampsia (preeclampsia), and cancer.

[0024] Other features and advantages of the invention will become apparent from the detailed description and claims. DETAILED DESCRIPTION OF THE INVENTION

[0025] Reference will now be made in detail to various embodiments of the present invention. Such embodiments are provided to illustrate, but not to limit, the present invention. Indeed, those skilled in the art will recognize upon reading this specification and viewing the drawings that various modifications and variations are possible.

[0026] definition As used herein, the term "acid isostere" includes, but is not limited to, the following functional groups where R is H or alkyl: [ka]

[0027] The term "alkyl" refers to a saturated, straight-chain or branched-chain hydrocarbon group having 1 to 20 carbon atoms. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and the like, as well as longer alkyl groups such as heptyl, octyl, and the like. Furthermore, the number of carbon atoms in the alkyl chain can be determined by the C 1-10 can be defined relative to the C atom as 1-10 is a carbon chain having 1 to 10 carbon atoms.

[0028] The term "alkoxy" as used herein refers to an alkyl group singly linked to oxygen, including --O-(alkyl), where alkyl is defined above.

[0029] As used herein, the term "amino" refers to the group --NH.sub.2.

[0030] The term "alkenyl" refers to a hydrocarbon group formed when a hydrogen atom is removed from an alkene group. Alkenyl compounds are named by replacing -e with -yl in the name of the parent alkene. An example includes HC=CH- (e.g., ethenyl or vinyl).

[0031] The term "alkynyl" refers to a fragment containing an open point of attachment of a carbon atom that is formed when a hydrogen atom attached to a triple-bonded carbon is removed from an alkyne molecule.

[0032] The term "haloalkyl" refers to any alkyl radical having one or more hydrogen atoms replaced with a halogen atom.

[0033] The term "phenyl" refers to a monovalent hydrocarbon radical (C6H5) formally derived from benzene by removal of a hydrogen atom.

[0034] The term "naphthyl" refers to an isomeric monovalent radical formally derived from naphthalene by removal of a hydrogen atom.

[0035] The term "pyrrole" refers to a heterocyclic aromatic organic compound that is a five-membered ring having the formula C4H4NH.

[0036] The term "imidazole" refers to an organic compound having the formula C3N2H4.

[0037] The term "thiophene" refers to a heterocyclic compound having the formula C4H4S.

[0038] The term "furan" refers to a heterocyclic organic compound consisting of a five-membered aromatic ring having four carbon atoms and one oxygen.

[0039] The term "thiazole" refers to a heterocyclic compound containing both sulfur and nitrogen and with the molecular formula C3H3NS.

[0040] The term "isothiazole" or 1,2-thiazole refers to an organic compound containing a five-membered aromatic ring consisting of three carbon atoms, one nitrogen atom, and one sulfur atom.

[0041] The term "thiadiazole" refers to a subfamily of azole compounds that are five-membered heterocyclic compounds containing one sulfur and two nitrogen atoms.

[0042] The term "oxazole" refers to the parent compound of a class of heterocyclic aromatic organic compounds. Oxazoles are azoles with oxygen and nitrogen separated by one carbon.

[0043] The term "isoxazole" refers to an azole having an oxygen atom adjacent to the nitrogen.

[0044] The term "oxadiazole" refers to a class of heterocyclic aromatic compounds of the azole family having the molecular formula C2H2N2O.

[0045] The term "pyridine" refers to a basic heterocyclic organic compound with the chemical formula CHN. Pyridine is structurally related to benzene, with one methine group replaced by a nitrogen atom.

[0046] The term "pyrazine" refers to a heterocyclic organic compound having the chemical formula C4H4N2. Pyrazine is less basic than pyridine, pyridazine, and pyrimidine.

[0047] The term "pyrimidine" refers to a heterocyclic organic compound similar to pyridine. Pyrimidine, one of the three diazines, has nitrogen atoms in positions 1 and 3 of the ring.

[0048] The term "pyridazine" is a heterocyclic organic compound with the molecular formula (CH)N. Pyrimidines contain a six-membered ring with two adjacent nitrogen atoms.

[0049] The term "pyrazole" refers to an organic compound having the formula CHN. Pyrazoles are heterocycles characterized by a five-membered ring of three carbon atoms and two adjacent nitrogen atoms.

[0050] The term "trizole" refers to any of the heterocyclic compounds with the molecular formula C2H3N3, which has a five-membered ring of two carbon atoms and three nitrogen atoms.

[0051] The term "tetrazole" refers to a class of synthetic organic heterocyclic compounds consisting of a five-membered ring of four nitrogen atoms and one carbon atom. The name tetrazole also refers to the parent compound having the formula CHN.

[0052] The term "chroman" or "chromane" refers to the compound with the chemical formula CH 10 It refers to heterocyclic compounds containing O.

[0053] The term "quinoline" refers to a heterocyclic organic compound having the chemical formula C9H7N.

[0054] The term "quinoxaline" or "benzopyrazine" refers to a heterocyclic compound containing a ring complex consisting of a benzene ring and a pyrazine ring.

[0055] The term "isoquinoline" refers to a heterocyclic aromatic organic compound. Isoquinoline is a structural isomer of quinoline. Isoquinoline and quinoline are benzopyridines, consisting of a benzene ring fused to a pyridine ring.

[0056] The term "phthalazine," "benzo-orthodiazine," or "benzopyridazine" refers to a heterocyclic organic compound with the molecular formula CHN. It is an isomer of other naphthyridines, including quinoxaline, cinnoline, and quinazoline.

[0057] The term "cinnoline" is a heterocyclic compound having the formula CHN. It is an isomer of other naphthyridines, including quinoxaline, phthalazine, and quinazoline.

[0058] The term "quinazoline" refers to an organic compound having the formula CHN. Quinazoline is a heterocycle with a bicyclic structure consisting of two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.

[0059] The term "indole" is a heterocyclic organic compound having the formula CHN. Indole has a bicyclic structure consisting of a six-membered benzene ring fused to a five-membered pyrrole ring.

[0060] The term "isoindole" is a benzo-fused pyrrole, an isomer of indole.

[0061] The term "indoline" is a heterocyclic organic compound having the chemical formula CHN. Indoline has a bicyclic structure consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.

[0062] The term "isoindoline" refers to a heterocyclic organic compound with the molecular formula CHN. The parent compound has a bicyclic structure consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.

[0063] The term "benzothiophene" refers to an organic compound having the molecular formula CHS.

[0064] The term "benzofuran" refers to a heterocyclic compound consisting of a fused benzene ring and a furan ring.

[0065] The term "isobenzofuran" refers to a heterocyclic compound consisting of a fused benzene ring and a furan ring. Isobenzofuran is an isomer of benzofuran.

[0066] The term "benzoxazole" refers to an organic compound having the molecular formula C7H5NO and containing a benzene-fused oxazole ring structure.

[0067] The term "benzothiazole" refers to a heterocyclic compound having the chemical formula C7H5NS.

[0068] The term "benzimidazole" refers to a heterocyclic organic compound. Benzimidazole is a bicyclic compound consisting of the fusion of benzene and imidazole.

[0069] The term "indazole" or "isoindazole" refers to a heterocyclic organic compound consisting of the fusion of a benzene and a pyrazole.

[0070] The term "benzodioxane" refers to isomeric compounds having the molecular formula C8H8O2.

[0071] The term "indane" or "indan" refers to an organic compound having the formula C6H4(CH2)3.

[0072] The term "acridine" refers to a compound of formula C 13 The term refers to organic compounds and nitrogen-containing heterocycles containing H9N. Acridine is a substituted derivative of the parent ring. It is a planar molecule structurally related to anthracene in which one of the central CH groups is replaced by nitrogen.

[0073] The term "phenazine" refers to an organic compound having the formula (C6H4)2N2. Phenazines are dibenzo-annulated pyrazines.

[0074] The term "xanthene" refers to an organic compound having the formula CH2[C6H4]2O.

[0075] The term "isochroman" has the formula CH 10 O and the following structure [ka] It refers to a compound having the formula:

[0076] The term "2,1,3-benzoxadiazole" has the following structure: [ka] It refers to an organic compound having the formula:

[0077] The term "2,1,3-benzothiazole" refers to a heterocyclic compound having the chemical formula C7H5NS.

[0078] The term "2,1,3-benzoselenadiazole" has the following structure: [ka] It refers to an organic compound having the formula:

[0079] The term "tetrahydroquinoline" refers to an organic compound that is a semi-hydrogenated derivative of quinoline.

[0080] The term "3,4-dihydro-2H-1,4-benzoxazine" has the following structure: [ka] It refers to an organic compound having the formula:

[0081] The term "1,5-naphthyridine" has the following structure: [ka] It refers to an organic compound having the formula:

[0082] The term "1,8-naphthyridine" refers to an organic compound having the formula C8H6N2.

[0083] The term "aryl" refers to a monocyclic, bicyclic, or tricyclic aromatic group, in which all rings of the group are aromatic and all ring atoms are carbon atoms. In the case of a bicyclic or tricyclic system, the individual aromatic rings are fused to each other. Examples of aryl groups are 6- and 10-membered aryls. Further examples of aryl groups include, but are not limited to, phenyl, naphthalene, and anthracene.

[0084] The term "cyano" as used herein refers to a substituent having a carbon atom attached to a nitrogen atom by a triple bond.

[0085] As used herein, the term "deuterium" refers to a stable isotope of hydrogen having one proton and one neutron.

[0086] As used herein, the term "halogen" refers to fluorine, chlorine, bromine, iodine, astatine, or tennessine. The term "halo" refers to a group containing a halogen.

[0087] The term "hydroxy" refers to an --OH group.

[0088] The term "oxo" refers to the group =0, which may be attached to a carbon or sulfur atom.

[0089] The term "N-oxide" refers to the oxidized form of a nitrogen atom.

[0090] The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic, fused polycyclic, bridged polycyclic, or spiropolycyclic carbocycle having from 3 to 15 carbon ring atoms. A non-limiting category of cycloalkyl groups is a saturated or partially saturated, monocyclic carbocycle having from 3 to 6 carbon atoms. Illustrative examples of cycloalkyl groups include the following moieties: [ka] These include, but are not limited to:

[0091] As used herein, the term "heterocycloalkyl" refers to a monocyclic or fused, bridged, or spiro-polycyclic ring structure that is saturated or partially saturated and has 3 to 12 ring atoms selected from carbon atoms and up to three heteroatoms selected from nitrogen, oxygen, and sulfur. The ring structure may optionally contain up to two oxo groups at the carbon or sulfur ring members, or N-oxides. Exemplary heterocycloalkyl moieties include: [ka] These include, but are not limited to:

[0092] The term "heteroaryl" refers to a monocyclic or fused polycyclic, aromatic heterocycle having 3 to 15 ring atoms selected from carbon, oxygen, nitrogen, and sulfur. Suitable heteroaryl groups do not include ring systems that are required to be charged to be aromatic, such as pyrylium. Suitable 5-membered heteroaryl rings (as monocyclic heteroaryls or as part of polycyclic heteroaryls) have one oxygen, sulfur, or nitrogen ring atom, or one nitrogen plus one oxygen or sulfur, or two, three, or four nitrogen ring atoms. Suitable 6-membered heteroaryl rings (as monocyclic heteroaryls or as part of polycyclic heteroaryls) have one, two, or three nitrogen ring atoms. Examples of heteroaryl groups include, but are not limited to, pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl.

[0093] The term "fused heteroaryl" refers to a heteroaryl, as defined above, having two constituent aromatic rings, wherein the two rings are fused together and at least one of the rings is a heteroaryl, as defined above. Fused heteroaryl includes fused heteroaryl groups containing 1, 2, 3, or 4 heteroatom ring atoms selected from O, N, or S. In certain embodiments, the heteroatom is N and may be an N-oxide. Fused heteroaryl also includes 8-, 9-, or 10-membered fused heteroaryl groups. Fused heteroaryl also includes 8-, 9-, or 10-membered fused heteroaryl groups having 1, 2, 3, or 4 heteroatom ring atoms selected from O, N, or S. Illustrative examples of fused heteroaryl include: [ka] These include, but are not limited to:

[0094] Those of ordinary skill in the art will recognize that the species of heteroaryl, cycloalkyl, and heterocycloalkyl groups listed or exemplified above are not exhaustive and that additional species may be selected within the scope of these defined terms.

[0095] As used herein, "liquid chromatography-mass spectrometry" or LC-MS is an analytical chemistry technique that combines the physical separation capabilities of liquid chromatography (or HPLC) with the mass analysis capabilities of mass spectrometry (MS).

[0096] As used herein, "proton nuclear magnetic resonance" or 1H NMR is the application of nuclear magnetic resonance in NMR spectroscopy to hydrogen-1 nuclei within a molecule of a substance to determine the structure of that molecule.

[0097] As used herein, the term "substituted" means that a particular group or moiety has one or more suitable substituents. As used herein, the term "unsubstituted" means that a particular group has no substituents. As used herein, the term "optionally substituted" means that a particular group is unsubstituted or substituted with a specified number of substituents. When the term "substituted" is used to describe a structural system, it means that substitution occurs at any valence-allowed position of the system.

[0098] The term "substituent" refers to an atom or group of atoms that replaces one or more hydrogen atoms of a hydrocarbon parent chain and becomes part of the resulting new molecule.

[0099] Any atom represented herein with unsatisfied valences is assumed to have a sufficient number of hydrogen atoms to satisfy the valences of the atom.

[0100] In any formula or description provided herein, any variable (e.g., alkyl, R a , R 1 ) appears in more than one place, the definition of the variable in each occurrence is independent of its definition in all other occurrences.

[0101] As used herein, numerical ranges are intended to include consecutive integers. For example, a range expressed as "from 0 to 4" or "0-4" includes 0, 1, 2, 3, and 4.

[0102] When a polyfunctional moiety is indicated, the point of attachment to the rest of the formula can be at any point on the polyfunctional moiety. In some embodiments, the point of attachment is indicated by a line or a hyphen. For example, aryloxy- refers to a moiety in which the oxygen atom is the point of attachment to the core molecule and the aryl is bonded to the oxygen atom.

[0103] As used herein, the term "subject" encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the mammalian class, such as humans, non-human primates (e.g., chimpanzees, apes, and monkey species), livestock (e.g., cows, horses, sheep, goats, pigs, etc.), domestic animals (e.g., rabbits, dogs, cats, etc.), and laboratory animals (e.g., rodents, e.g., rats, mice, and guinea pigs, etc.). Examples of non-mammals include, but are not limited to, birds, fish, etc. In one embodiment of the present invention, the mammal is a human.

[0104] The term "patient" or "subject" includes both humans and animals.

[0105] The term "effective amount" or "therapeutically effective amount" refers to an amount of an agent sufficient to provide a desired biological result. The result may be a reduction and / or alleviation of the signs, symptoms, or causes of a disease or medical condition, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a compound or a composition containing a compound required to bring about a clinically relevant change in a disease state, symptom, or medical condition. An appropriate "effective" amount in any individual case can be determined by one of ordinary skill in the art using routine experimentation. Thus, the phrase "effective amount" generally refers to the amount of an active substance that exerts a therapeutically desired effect.

[0106] As used herein, the term "treating" or "treatment" encompasses both "preventive" and "curative" treatment. As used herein, the phrase "preventive treatment" refers to postponing the onset of a disease, disease symptom, or medical condition, suppressing symptoms that may appear, or reducing the risk of the onset or recurrence of a disease or symptom. As used herein, the phrase "curative treatment" refers to reducing the severity or preventing the worsening of an existing disease, symptom, or condition. Thus, "treatment" includes improving or preventing the worsening of existing disease symptoms, preventing the occurrence of further symptoms, improving or preventing the metabolic causes underlying symptoms, inhibiting a disorder or disease, for example, arresting the onset of a disorder or disease, alleviating a disorder or disease, regressing a disorder or disease, alleviating a condition caused by a disease or disorder, or arresting the symptoms of a disease or disorder.

[0107] Specific Embodiments Formula I In one of its embodiments, the present invention provides a compound of formula (I) [ka] or a pharmaceutically acceptable salt or ester thereof, R 1 and R 6 ~R 9each independently represents -H, -CN, -COOH, -CONH2, B(OR a )2, Acid Isostere, Halo, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n is heterocycloalkyl, B(OR a )2R a is H or alkyl, B(OR a )2, B is boron, C n n is 1 to 10, R 2 ~R 5 each independently represents -H, -CN, -COOH, -COOMe, -CONH2, B(OR a )2, Acid isostere, Halo, -CONHOH, -NH-SO2-C1~C6-Alkyl, -NHSO2Ar, C n Alkyl, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n is heterocycloalkyl, Ar in -NHSO2Ar is phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, or benzothiophene. selected from the group consisting of phene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene; C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, and C n each heterocycloalkyl is unsubstituted or substituted with 1 to 5 substituents; each substituent is the same or different; Each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl and -C q -UC q is selected from the group consisting of -C q -UC q Each q is independently 0 to 10; -C q -UC q wherein U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1); Each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; Each R1 in N(R1)(R1) is unsubstituted, may be the same or different, and may be H, 2 substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; Q is a bond or O; If X is O or S, then R 6 X is C, N, O or S, so that "A" is [ka] is a saturated or unsaturated ring represented by Y, T, W, and Z are independently a bond, C, N, O, alkyl having 1 to 4 carbon atoms, or alkenyl having 1 to 4 carbon atoms; n is 0, 1, 2, or 3.

[0108] In one embodiment, the present invention provides a compound comprising R 1 and R 2 is linked to form a fused heteroaryl.

[0109] In one embodiment, the present invention provides a compound comprising R 2 and R 3 is linked to form a fused heteroaryl.

[0110] In one embodiment, the present invention provides a compound comprising R 3 and R 4 is linked to form a fused heteroaryl.

[0111] In one embodiment, the present invention provides a compound comprising R 4 and R 5 is linked to form a fused heteroaryl.

[0112] In one embodiment, the present invention provides a compound comprising R 5 and R 6 wherein at least one of is linked to form a fused heteroaryl.

[0113] In one embodiment, the present invention provides a compound comprising R 6 and R 7 is linked to form a fused heteroaryl.

[0114] In one embodiment, the present invention provides a compound comprising R 7 and R 8 is linked to form a fused heteroaryl.

[0115] In one embodiment, the present invention provides a compound comprising R 8 and R 9 is linked to form a fused heteroaryl.

[0116] In one embodiment, the present invention provides a compound comprising R 1 and R 2 and wherein at least one of is linked to form a fused heterocycloalkyl.

[0117] In one embodiment, the present invention provides a compound comprising R 2 and R 3 and wherein at least one of is linked to form a fused heterocycloalkyl.

[0118] In one embodiment, the present invention provides a compound comprising R 3 and R 4 and wherein at least one of is linked to form a fused heterocycloalkyl.

[0119] In one embodiment, the present invention provides a compound comprising R 4 and R 5 and wherein at least one of is linked to form a fused heterocycloalkyl.

[0120] In one embodiment, the present invention provides a compound comprising R 5 and R 6 and wherein at least one of is linked to form a fused heterocycloalkyl.

[0121] In one embodiment, the present invention provides a compound comprising R 6 and R 7 and wherein at least one of is linked to form a fused heterocycloalkyl.

[0122] In one embodiment, the present invention provides a compound comprising R 7 and R 8 and wherein at least one of is linked to form a fused heterocycloalkyl.

[0123] In one embodiment, the present invention provides a compound comprising R 8 and R 9 and wherein at least one of is linked to form a fused heterocycloalkyl.

[0124] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0125] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of R is -H; 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0126] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of R is -CN; 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0127] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of R is -COOH; 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0128] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of R is -CONH2, 2 ~R 5, W, T, Y, Z, Q and X are as defined.

[0129] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of B(OR a )2 and B(OR a )2, B is boron, and B(OR a )2R a is H and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0130] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of B(OR a )2 and B(OR a )2, B is boron, and B(OR a )2R a is alkyl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0131] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 at least one of R is an acid isostere disclosed herein; 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0132] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1and R 6 ~R 9 At least one of the groups is a halo, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0133] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, and C n The alkyl is unsubstituted and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0134]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, and C n The alkyl is substituted with one substituent, the substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0135]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, and C n The alkyl is substituted with 2 to 5 substituents, the substituents being identical and each substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0136]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, and C n The alkyl is substituted with 2 to 5 substituents, the substituents being different and each substituent being H, 2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0137] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The n of the alkyl is 1 to 10, the number of substituents is 1, the substituent is H, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0138] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is 2 H and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0139] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the amount of the substituent is 1, the substituent is halo, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0140] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an amino group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0141] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an alkoxy group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0142] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is a cyano group, and R2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0143] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is aminoalkyl-, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0144] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is (amino)alkoxy-, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0145] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an alkyl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0146] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an -alkenyl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0147] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an alkynyl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0148] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an alkoxy group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0149] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is a hydroxy group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0150] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an alkylhydroxy group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0151] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an aryloxy group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0152] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an alkyl (aryl) group, and R 2~R 5 , W, T, Y, Z, Q and X are as defined.

[0153] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an (alkoxyalkyl)amino group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0154] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an aryl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0155] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an aryl(halo) group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0156] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is a heteroaryl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0157] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the amount of the substituent is 1, the substituent is a hydroxyl-alkyl-group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0158] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is a hydroxyl-aryl-group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0159] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an (aryl) alkyl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0160] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an -S(O)2-alkyl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0161] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, the substituent is an -S(O)2-aryl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0162] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C nn is 1 to 10, the number of substituents is 1, the substituent is a -C(O) alkyl group, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0163] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is aryl and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0164] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is heteroaryl and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0165] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is cycloalkyl and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0166] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is heterocycloalkyl and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0167] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C nn is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is O and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0168] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is S and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0169] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is SO2 and R 2 ~R5 , W, T, Y, Z, Q and X are as defined.

[0170] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0171] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n alkyl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0172] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n alkenyl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0173] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n alkynyl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0174] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n aryl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0175] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n aminoalkyl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0176] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, Cn n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n haloalkyl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0177] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n heteroaryl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0178] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -Cq -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n is cycloalkyl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0179] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently C n heterocycloalkyl, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0180] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UCq U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0181] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is substituted with one substituent, the substituent being H, 2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0182] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 2 to 5 substituents, each substituent being the same, and each substituent being selected from the group consisting of H, 2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0183] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 2 to 5 substituents, each substituent being different, and each substituent being selected from the group consisting of H, 2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0184]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, each substituent is the same, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0185]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the nalkyl, n is 1 to 10, the number of substituents is 2 to 5, each substituent is different, and each substituent is selected from the group consisting of H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0186]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, each substituent is the same, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl or -C q -UC q and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0187]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, each substituent is different, and each substituent is selected from the group consisting of H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl or -C q -UC q and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0188] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0189] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the nalkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is aryl and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0190] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is heteroaryl and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0191] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC qU is cycloalkyl and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0192] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is heterocycloalkyl and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0193] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is O and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0194] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is S and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0195] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is SO2 and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0196] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is -C q -UC q and -C q -UCq Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0197] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0198] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, each substituent being the same, and each substituent being selected from the group consisting of H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0199] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, n is 1 to 10, the number of substituents is 2 to 5, and at least one of the substituents is -C q -UC q and -C q -UC qEach q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, each substituent being different, and each substituent being selected from the group consisting of H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0200] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0201] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C nn is 1 to 10, and C n Alkenyl is unsubstituted and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0202]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0203]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC qU is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0204]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0205]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0206]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) may be different and is H, 2substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0207]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, the substituents being identical and including H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0208]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, which are different and independently selected from H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0209]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0210]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5, W, T, Y, Z, Q and X are as defined.

[0211]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0212]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkenyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is different and is H, 2 substituted with 2 to 5 substituents which may include H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0213] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R9 At least one of the n aryl, C n n is 1 to 10, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0214] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n Alkenyl is unsubstituted and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0215]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0216]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0217]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC qU is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0218]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C nAlkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0219]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) may be different and is H,2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0220]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, the substituents being identical and including H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0221]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, which are different and independently selected from H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0222]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0223]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0224]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0225]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R9 At least one of the n aryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is different and is H, 2 substituted with 2 to 5 substituents which may include H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0226] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and R 2 ~R5 , W, T, Y, Z, Q and X are as defined.

[0227] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n Alkenyl is unsubstituted and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0228]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0229]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0230]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, Cn Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0231]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H,2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0232]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) may be different and is H, 2substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0233]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, the substituents being identical and including H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0234]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, which are different and independently selected from H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0235]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0236]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R5 , W, T, Y, Z, Q and X are as defined.

[0237]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0238]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is different and is H, 2 substituted with 2 to 5 substituents which may include H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0239] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R9 At least one of the n haloalkyl, C n n is 1 to 10, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0240] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n Alkenyl is unsubstituted and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0241]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0242]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0243]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC qU is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0244]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, Cn Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0245]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) may be different and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0246]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, the substituents being identical and including H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0247]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, which are different and independently selected from H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0248]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, Cn Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0249]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0250]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0251]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n haloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is different and is H, 2substituted with 2 to 5 substituents which may include H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0252] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0253] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n Alkenyl is unsubstituted and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0254]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0255]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R5 , W, T, Y, Z, Q and X are as defined.

[0256]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0257]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0258]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) may be different and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0259]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C nThe alkenyl is substituted with 2 to 5 substituents, the substituents being identical and including H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0260]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, which are different and independently selected from H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0261]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0262]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC qU is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0263]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C nAlkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0264]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heteroalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is different and is H, 2 substituted with 2 to 5 substituents which may include H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0265] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0266] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n Alkenyl is unsubstituted and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0267]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0268]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, Cn alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0269]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R5 , W, T, Y, Z, Q and X are as defined.

[0270]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0271]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) may be different and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0272]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, the substituents being identical and including H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0273]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, which are different and independently selected from H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0274]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0275]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC qU is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0276]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C nAlkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0277]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is different and is H, 2 substituted with 2 to 5 substituents which may include H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0278] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0279] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n aminoaryl, C n n is 1 to 10, and C n Alkenyl is unsubstituted and R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0280]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0281]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C nAlkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0282]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2-R 5 , W, T, Y, Z, Q and X are as defined.

[0283]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0284]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with one substituent, the substituent being -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) may be different and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0285]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, the substituents being identical and including H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0286]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, which are different and independently selected from H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0287]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , W, T, Y, Z, Q and X are as defined.

[0288]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q-UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is H, 2 substituted by one substituent including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0289]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC qU is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is the same and is H, 2 substituted with 2 to 5 substituents including H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0290]

[0013] Embodiments of the present invention include compounds of formula (I), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n is cycloalkyl, C n n is 1 to 10, and C n The alkenyl is substituted with 2 to 5 substituents, at least one of which is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, Cn Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is different and is H, 2 substituted with 2 to 5 substituents which may include H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 -R 5 , W, T, Y, Z, Q and X are as defined.

[0291] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 each independently represents -H, -CN, -COOH, -COOMe, -CONH2, B(OR a )2, Acid isostere, Halo, -CONHOH, -NH-SO2-C1~C6-Alkyl, -NHSO2Ar, C n Alkyl, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n heterocycloalkyl, and B(OR a )2, B is boron, B(OR a )2R a is H or alkyl, and R 1 , R 6 ~R9 , W, T, Y, Z, Q and X are as defined.

[0292] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the above is -NHSO2Ar, and Ar in -NHSO2Ar is phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, iso is selected from the group consisting of indoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine, and xanthene; 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0293] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is naphthyl, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0294] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is pyrrole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0295] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, where Ar is imidazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0296] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is thiophene, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0297] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is isothiazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0298] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is thiadiazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0299] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is oxazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0300] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is isoxazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0301] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is oxadiazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0302] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is pyridine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0303] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is pyrazine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0304] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is pyrimidine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0305] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is pyridazine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0306] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is pyrazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0307] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of R is -NHSOAr, where Ar is triazole, 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0308] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is tetrazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0309] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is chroman, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0310] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is an isochroman, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0311] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is quinoline, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0312] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is quinoxaline, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0313] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is isoquinoline, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0314] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is phthalazine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0315] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is cinnoline, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0316] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is quinazoline, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0317] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is indole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0318] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is isoindole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0319] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is indoline, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0320] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is isoindoline, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0321] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is benzothiophene, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0322] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is benzofuran, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0323] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is isobenzofuran, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0324] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is benzoxazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0325] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 2,1,3-benzoxadiazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0326] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is benzothiazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0327] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 2,1,3-benzothiazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0328] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 2,1,3-benzoselenadiazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0329] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is benzimidazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0330] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of R is -NHSOAr, Ar is indazole, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0331] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is benzodioxane, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0332] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is indane, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0333] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 1,2,3,4-tetrahydroquinoline, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0334] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 3,4-dihydro-2H-1,4-benzoxazine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0335] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is 1,5-naphthyridine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0336] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is 1,8-naphthyridine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0337] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, where Ar is acridine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0338] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is phenazine, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0339] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is xanthene, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0340] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl or C n Heterocycloalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0341] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5At least one of the C substituted with one substituent n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, or C n Heterocycloalkyl, C n n is 1 to 10, and the substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl or -C q -UC q and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0342] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with one substituent n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, or C n Heterocycloalkyl, C n n is 1 to 10, and the substituent is -C q -UC q and -C q -UCq Each q is independently 0 to 10; q -UC q U is one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0343] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with one substituent n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, or C n Heterocycloalkyl, C n n is 1 to 10, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0344] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C is substituted with one substituent. n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, or C n Heterocycloalkyl, C n n is 1 to 10, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 1 to 5 identical substituents, the substituents being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0345] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C is substituted with one substituent. n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, or C n Heterocycloalkyl, C n n is 1 to 10, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 1 to 5 different substituents, each of the 1 to 5 substituents being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0346] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, the amount of substituents is 1, and the substituents are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0347] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, the number of substituents is 2 to 5, each substituent is the same, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; n n is 1 to 10, and R 1 , R 6 ~R 9, W, T, Y, Z, Q and X are as defined.

[0348] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, the number of substituents is 2 to 5, each substituent is different and is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0349] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, the amount of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, and C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0350] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, the amount of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0351] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 1 , R 6 ~R 9, W, T, Y, Z, Q and X are as defined.

[0352] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, C n n is 1 to 10, the number of substituents is 1, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and each of the 1 to 5 substituents may be the same or different and may be H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0353] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one ofn alkenyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0354] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n alkenyl, C n n is 1 to 10, each substituent may be the same or different, and may be H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0355] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkenyl, C n n is 1 to 10, the number of substituents is 2 to 5, and at least one of each substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, Cn Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0356] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Alkynyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0357] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n Alkynyl, C n n is 1 to 10, and R 1 , R 6 ~R 9, W, T, Y, Z, Q and X are as defined.

[0358] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n Alkynyl, C n n is 1 to 10, and the substituents are H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0359] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Alkynyl, C n n is 1 to 10, the number of substituents is 1 to 5, and the substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0360] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n aryl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0361] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n aryl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0362] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n aryl, C n n is 1 to 10, the amount of substituents is 1 to 5, the substituents are the same or different, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl or -C q -UC q and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0363] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n aryl, C n n is 1 to 10, the number of substituents is 1 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0364] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n aminoalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0365] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n aminoalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0366] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n aminoalkyl, C n n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -C q -UC q and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0367] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n aminoalkyl, C n n is 1 to 10, the number of substituents is 1 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0368] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n haloalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0369] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n haloalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0370] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n haloalkyl, C n n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C q -UC q or —C(O)alkyl, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0371] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n haloalkyl, C n n is 1 to 10, the number of substituents is 1 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0372] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Heteroaryl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0373] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n Heteroaryl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0374] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n Heteroaryl, C n n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -C q -UC q and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0375] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Heteroaryl, C n n is 1 to 10, the number of substituents is 1 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0376] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n is cycloalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0377] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n is cycloalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0378] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n is cycloalkyl, C n n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0379] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n is cycloalkyl, C n n is 1 to 10, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0380] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Heterocycloalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0381] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n Heterocycloalkyl, C n n is 1 to 10, and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0382] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n Heterocycloalkyl, C n n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -C q -UC q and R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0383] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n Heterocycloalkyl, C n n is 1 to 10, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , W, T, Y, Z, Q and X are as defined.

[0384] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Q is a bond, and R 1 ~R 9 , W, T, Y, Z, and X are as defined.

[0385] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Q is O, and R 1 ~R 9 , W, T, Y, Z, and X are as defined.

[0386] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, X is C, and R 1 ~R 9 , W, T, Y, Z, and Q are as defined.

[0387] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, X is N, and R 1 ~R 9 , W, T, Y, Z, and Q are as defined.

[0388] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, X is O, and R 6 does not exist, and R 1 ~R 5 , R 7 ~R 9 , W, T, Y, Z, and Q are as defined.

[0389] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, X is S, and R 6 does not exist, and R 1 ~R 5 , R 7 ~R 9 , W, T, Y, Z, and Q are as defined.

[0390] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, A is unsaturated, and R 1 ~R 9 , W, T, Y, Z, X, and Q are as defined.

[0391] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, A is saturated, and R 1 ~R 9 , W, T, Y, Z, X and Q are as defined.

[0392] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Y is a bond, and R1 ~R 9 , W, T, Z, X and Q are as defined.

[0393] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Y is C, and R 1 ~R 9 , W, T, Z, X and Q are as defined.

[0394] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Y is N, and R 1 ~R 9 , W, T, Z, X and Q are as defined.

[0395] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Y is O, and R 1 ~R 9 , W, T, Z, X and Q are as defined.

[0396] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Y is alkyl having 1 to 4 carbon atoms, and R 1 ~R 9 , W, T, Z, X and Q are as defined.

[0397] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Y is alkenyl having 1 to 4 carbon atoms, and R 1 ~R 9 , W, T, Z, X and Q are as defined.

[0398] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 to 3, and R 1 ~R 9 , W, T, Z, Y, X and Q are as defined.

[0399] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, T is a bond, and R 1 ~R 9 , W, Y, Z, X and Q are as defined.

[0400] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, T is C, and R 1 ~R 9 , W, Y, Z, X and Q are as defined.

[0401] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, T is N, and R 1 ~R 9 , W, Y, Z, X and Q are as defined.

[0402] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, T is O, and R 1 ~R 9 , W, Y, Z, X and Q are as defined.

[0403] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, T is alkyl having 1 to 4 carbon atoms, and R 1 ~R 9 , W, Y, Z, X and Q are as defined.

[0404] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, T is alkenyl having 1 to 4 carbon atoms, and R 1 ~R 9 , W, Y, Z, X and Q are as defined.

[0405] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, W is a bond, and R 1 ~R 9 , Y, T, Z, X and Q are as defined.

[0406] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, W is C, and R 1 ~R 9 , Y, T, Z, X and Q are as defined.

[0407] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, W is N, and R 1 ~R 9 , Y, T, Z, X and Q are as defined.

[0408] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, W is O, and R 1 ~R 9 , Y, T, Z, X and Q are as defined.

[0409] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, W is alkyl having 1 to 4 carbon atoms, and R 1 ~R 9 , Y, T, Z, X and Q are as defined.

[0410] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, W is alkenyl having 1 to 4 carbon atoms, and R 1 ~R 9 , Y, T, Z, X and Q are as defined.

[0411] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Z is a bond, and R 1 ~R 9 , W, T, Y, X and Q are as defined.

[0412] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Z is C, and R 1 ~R 9 , W, T, Y, X and Q are as defined.

[0413] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Z is N, and R 1 ~R 9 , W, T, Y, X and Q are as defined.

[0414] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Z is O, and R 1 ~R 9 , W, T, Y, X and Q are as defined.

[0415] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Z is alkyl having 1 to 4 carbon atoms, and R 1 ~R 9 , W, T, Y, X and Q are as defined.

[0416] One embodiment of the present invention includes a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Z is alkenyl having 1 to 4 carbon atoms, and R 1 ~R 9 , W, T, Y, X and Q are as defined.

[0417] Formula II In a further embodiment, the present invention provides a compound of formula II [ka] or a pharmaceutically acceptable salt or ester thereof, R 1 and R 6 ~R 9 are independently -H, -CN, -COOH, -CONH2, B(OR a )2, Acid Isostere, Halo, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; halo is selected from the group consisting of -F, -Cl, -Br, -I, -At, and -Ts; R a is H or alkyl, B is boron, n is 1 to 10, R 2 ~R 5 each independently represents -H, -CN, -COOH, -COOMe, -CONH2, B(OR a )2, Acid isostere, Halo, -CONHOH, -NH-SO2-C1~C6-Alkyl, -NHSO2Ar, C n Alkyl, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; Ar in -NHSO2Ar is phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzo selected from thiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5-naphthyridine, 1,8-naphthyridine, acridine, phenazine and xanthene; C n Alkyl, C n Alkenyl, C n each of the alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl is unsubstituted or substituted with an amount of 1 to 5 substituents; each substituent is the same or different; Each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxylalkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl and -C q -UC q is selected from the group consisting of -C q -UC q Each q is independently 0 to 10; -Cq -UC q wherein U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1); Each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; Each R1 in N(R1)(R1) is unsubstituted, may be the same or different, and may be H, 2 substituted with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; Q is a bond or O; If X is O or S, then R 6 X is C, N, O or S, so that X is C, N, O or S; n is 0, 1, 2, or 3.

[0418] In some embodiments, the present invention includes compounds of Formula II, wherein the heterocycloalkyl group is R 7 , R 8 or R 9 Combine two of them [ka] It is formed by forming

[0419] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of R is -CN; 2 ~R 5 , Q and X are as defined.

[0420] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of R is -COOH; 2 ~R 5 , Q and X are as defined.

[0421] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of R is -CONH2, 2 ~R 5 , Q and X are as defined.

[0422] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of B(OR a )2 and B(OR a )2, B is boron, and B(OR a )2R a is H and R 2 ~R 5 , Q and X are as defined.

[0423] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of B(OR a )2 and B(OR a )2, B is boron, and B(OR a )2R a is alkyl, and R 2 ~R 5 , Q and X are as defined.

[0424] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 at least one of R is an acid isostere disclosed herein; 2 ~R 5 , Q and X are as defined.

[0425] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the groups is a halo, and R 2 ~R 5 , Q and X are as defined.

[0426] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0427] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of n alkyl, C n n of alkyl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0428]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the C substituted with 1 to 5 substituents n alkyl, C n The alkyl group n is 1 to 10, and each substituent may be the same or different, and each substituent may be H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -C q -UC q and R 2 ~R 5 , Q and X are as defined.

[0429]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the C substituted with 1 to 5 substituents n alkyl, Cn The alkyl group n is 1 to 10, and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 2 ~R 5 , Q and X are as defined.

[0430]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the C substituted with 1 to 5 substituents n alkyl, C n The alkyl group n is 1 to 10, and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; R 2 ~R 5 , Q and X are as defined.

[0431] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of then alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is H, and R 2 ~R 5 , Q and X are as defined.

[0432] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is 2 H and R 2 ~R 5 , Q and X are as defined.

[0433] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, the substituent is halo, and R 2 ~R 5 , Q and X are as defined.

[0434] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one of the substituents is an amino group, and R 2 ~R5 , Q and X are as defined.

[0435] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is an alkoxy group, R 2 ~R 5 , Q and X are as defined.

[0436] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one of the substituents is a cyano group, and R 2 ~R 5 , Q and X are as defined.

[0437] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The n of alkyl is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is aminoalkyl-; R 2 ~R 5 , Q and X are as defined.

[0438] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is (amino)alkoxy-, R 2 ~R 5 , Q and X are as defined.

[0439] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is -alkyl group, R 2 ~R 5 , Q and X are as defined.

[0440] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The n of the alkyl is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is an -alkenyl group; R 2 ~R 5 , Q and X are as defined.

[0441] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6~R 9 At least one of the n alkyl, C n The n of the alkyl is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is an -alkynyl group; R 2 ~R 5 , Q and X are as defined.

[0442] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The n of the alkyl is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is an alkoxy group; R 2 ~R 5 , Q and X are as defined.

[0443] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one of the substituents is a hydroxy group, and R 2 ~R 5 , Q and X are as defined.

[0444] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C nn of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is an alkylhydroxy group, R 2 ~R 5 , Q and X are as defined.

[0445] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one of the substituents is an aryloxy group, and R 2 ~R 5 , Q and X are as defined.

[0446] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The n of the alkyl is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is an -alkyl (aryl) group; R 2 ~R 5 , Q and X are as defined.

[0447] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one of the substituents is an (alkoxyalkyl)amino-group, R 2 ~R5 , Q and X are as defined.

[0448] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is an aryl group, R 2 ~R 5 , Q and X are as defined.

[0449] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is an -aryl(halo) group; R 2 ~R 5 , Q and X are as defined.

[0450] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is a heteroaryl group, and R 2 ~R 5 , Q and X are as defined.

[0451] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is a hydroxyl-alkyl-group, R 2 ~R 5 , Q and X are as defined.

[0452] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The n of the alkyl is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is a hydroxyl-aryl-group; R 2 ~R 5 , Q and X are as defined.

[0453] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is an (aryl) alkyl-group, R 2 ~R 5 , Q and X are as defined.

[0454] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is -S(O)2- alkyl group, R 2 ~R 5 , Q and X are as defined.

[0455] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one of the substituents is -S(O)2-aryl group, R 2 ~R 5 , Q and X are as defined.

[0456] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n n of alkyl is 1 to 10, the number of substituents is 1 to 5, at least one substituent is a -C(O) alkyl group, R 2 ~R 5 , Q and X are as defined.

[0457] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, Cn The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UC q and R 2 ~R 5 , Q and X are as defined.

[0458] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UC q and -C q -UC q each q is independently 0 to 10, U is heteroaryl, and R 2 ~R 5 , Q and X are as defined.

[0459] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UC q and -C q -UC q each q is independently 0 to 10, U is cycloalkyl, and R 2 ~R 5 , Q and X are as defined.

[0460] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UC q and -C q -UC q each q is independently 0 to 10, U is heterocycloalkyl, and R 2 ~R 5 , Q and X are as defined.

[0461] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UC q and -C q -UC q each q is independently 0 to 10, U is O, and R 2 ~R 5 , Q and X are as defined.

[0462] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UCq and -C q -UC q each q is independently 0 to 10, U is S, and R 2 ~R 5 , Q and X are as defined.

[0463] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UC q and -C q -UC q each q is independently 0 to 10, U is SO2, and R 2 ~R 5 , Q and X are as defined.

[0464]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The n of the alkyl is 1 to 10, the number of substituents is 1 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; R 2 ~R5 , Q and X are as defined.

[0465]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The n of the alkyl is 1 to 10, the number of substituents is 1 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 2 ~R 5 , Q and X are as defined.

[0466] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the n alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C nalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, each substituent being the same or different, and each substituent being selected from the group consisting of H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 2 ~R 5 , Q and X are as defined.

[0467] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of the C substituted with 1 to 5 identical or different substituents n alkyl, C n n of alkyl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0468] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of C is unsubstituted or substituted with 1 to 5 identical or different substituents. n alkenyl, C n n of alkenyl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0469] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of C is unsubstituted or substituted with 1 to 5 identical or different substituents. n aryl, C n Aryl n is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0470] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of C is unsubstituted or substituted with 1 to 5 identical or different substituents. n aminoalkyl, C n n of the aminoalkyl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0471] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of C is unsubstituted or substituted with 1 to 5 identical or different substituents. n haloalkyl, C n n of haloalkyl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0472] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R9 At least one of C is unsubstituted or substituted with 1 to 5 identical or different substituents. n Heteroaryl, C n n in heteroaryl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0473] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of C is unsubstituted or substituted with 1 to 5 identical or different substituents. n is cycloalkyl, C n n of cycloalkyl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0474] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 1 and R 6 ~R 9 At least one of C is unsubstituted or substituted with 1 to 5 identical or different substituents. n Heterocycloalkyl, C n n of heterocycloalkyl is 1 to 10, and R 2 ~R 5 , Q and X are as defined.

[0475] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of R is -H, 1 , R 6 ~R 9 , Q and X are as defined.

[0476] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of R is -CN, 1 , R 6 ~R 9 , Q and X are as defined.

[0477] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of R is -COOH, 1 , R 6 ~R 9 , Q and X are as defined.

[0478] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the is -COOMe and R 1 , R 6 ~R 9 , Q and X are as defined.

[0479] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -CONH2, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0480] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of B(ORa )2, B is boron, and R a is H and R 1 , R 6 ~R 9 , Q and X are as defined.

[0481] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of B(OR a )2, B is boron, and R a is alkyl, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0482] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the isosteres is an acid, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0483] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the is a halo, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0484] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the is -CONHOH, and R 1 , R 6 ~R 9, Q and X are as defined.

[0485] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of R is -NH-SO-C-alkyl; 1 , R 6 ~R 9 , Q and X are as defined.

[0486] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is phenyl, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0487] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is naphthyl, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0488] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is pyrrole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0489] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, where Ar is imidazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0490] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is thiophene, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0491] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is isothiazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0492] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is thiadiazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0493] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R2 ~R 5 at least one of is -NHSOAr, Ar is oxazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0494] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is isoxazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0495] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is oxadiazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0496] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is pyridine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0497] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is pyrazine, and R1 , R 6 ~R 9 , Q and X are as defined.

[0498] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is pyrimidine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0499] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is pyridazine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0500] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is pyrazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0501] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of R is -NHSOAr, where Ar is triazole, 1 , R 6 ~R 9 , Q and X are as defined.

[0502] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is tetrazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0503] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is chroman, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0504] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is an isochroman, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0505] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is quinoline, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0506] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is quinoxaline, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0507] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is isoquinoline, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0508] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is phthalazine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0509] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is cinnoline, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0510] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2~R 5 at least one of is -NHSOAr, Ar is quinazoline, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0511] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is indole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0512] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is isoindole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0513] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is indoline, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0514] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is isoindoline, and R 1 , R6 ~R 9 , Q and X are as defined.

[0515] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is benzothiophene, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0516] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is benzofuran, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0517] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is isobenzofuran, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0518] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is benzoxazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0519] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 2,1,3-benzoxadiazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0520] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is benzothiazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0521] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 2,1,3-benzothiazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0522] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 2,1,3-benzoselenadiazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0523] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is benzimidazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0524] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of R is -NHSOAr, Ar is indazole, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0525] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is benzodioxane, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0526] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is indane, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0527] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R2 ~R 5 at least one of is -NHSOAr, Ar is 1,2,3,4-tetrahydroquinoline, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0528] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is 3,4-dihydro-2H-1,4-benzoxazine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0529] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the groups is -NHSOAr, where Ar is 1,5-naphthyridine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0530] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is 1,8-naphthyridine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0531] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5At least one of is -NHSOAr, where Ar is acridine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0532] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of is -NHSOAr, Ar is phenazine, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0533] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 at least one of is -NHSOAr, Ar is xanthene, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0534] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n alkyl, n is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0535] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents nalkyl, each substituent being H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; C n n of alkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0536]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, the number of substituents is 1 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q each q is independently 0 to 10, U is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and C n n of alkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0537]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n alkyl, and at least one substituent is -C q -UCq and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl; n n of alkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0538] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkyl, C n The alkyl group n is 1 to 10, the number of substituents is 1 to 5, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R in N(R)(R) is unsubstituted; R 1 , R 6 ~R 9 , Q and X are as defined.

[0539] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of then alkyl, C n The alkyl n is 1 to 10, the number of substituents is 1 to 5, and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and each R1 in N(R1)(R1) is substituted with 1 to 5 identical or different substituents, each of which is selected from the group consisting of H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0540] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n alkenyl, C n n of alkenyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0541] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n alkenyl, C n n of alkenyl is 1 to 10, the number of substituents is 1 to 5, which may be the same or different, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0542]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n alkenyl, C n n of alkenyl is 1 to 10, and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 1 , R 6 ~R 9 , Q and X are as defined.

[0543] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 substituents n alkenyl, C n n of alkenyl is 1 to 10, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0544] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Alkynyl, Cn n of alkynyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0545] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n Alkynyl, C n n of alkynyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0546] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n Alkynyl, C n The n of the alkynyl is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0547]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2~R 5 At least one of the n Alkynyl, C n The n of the alkynyl is 1 to 10, the number of substituents is 1 to 5, and each substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10, and -C q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 1 , R 6 ~R 9 , Q and X are as defined.

[0548] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Alkynyl, C n The n of the alkynyl is 1 to 10, the number of substituents is 1 to 5, and each substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0549] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n aryl, C n Aryl n is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0550] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n aryl, C n Aryl n is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0551] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents naryl, C n The aryl n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0552]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n aryl, C n The aryl n is 1 to 10, and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 1 , R 6 ~R 9 , Q and X are as defined.

[0553] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents naryl, C n The aryl n is 1 to 10, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0554] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n aminoalkyl, C n n of the aminoalkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0555] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n aminoalkyl, C n n of the aminoalkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0556] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n aminoalkyl, C n The aminoalkyl n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0557]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n aminoalkyl, C n The aminoalkyl group has n of 1 to 10 and at least one substituent selected from the group consisting of -Cq -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 1 , R 6 ~R 9 , Q and X are as defined.

[0558] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n aminoalkyl, C n The aminoalkyl group has n of 1 to 10, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0559] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n haloalkyl, C n n of haloalkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0560] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n haloalkyl, C n n of haloalkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0561] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituentsn haloalkyl, C n n of haloalkyl is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0562]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n haloalkyl, C n The n of the haloalkyl is 1 to 10, and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 1 , R 6 ~R 9 , Q and X are as defined.

[0563] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5At least one of the C substituted with 1 to 5 identical or different substituents n haloalkyl, C n The n of the haloalkyl is 1 to 10, and at least one of the substituents is —C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0564] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Heteroaryl, C n n in heteroaryl is 1 to 10, and R 1 , R 6 ~R 9, Q and X are as defined.

[0565] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n Heteroaryl, C n n in heteroaryl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0566] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n Heteroaryl, C n The heteroaryl n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0567]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents nHeteroaryl, C n Heteroaryl n is 1 to 10 and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 1 , R 6 ~R 9 , Q and X are as defined.

[0568] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n Heteroaryl, C n The heteroaryl n is 1 to 10, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0569] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n is cycloalkyl, C n n of cycloalkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0570] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n is cycloalkyl, C n n of cycloalkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0571] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituentsn is cycloalkyl, C n The cycloalkyl n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0572]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n is cycloalkyl, C n The cycloalkyl n is 1 to 10, and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 1 , R 6 ~R 9 , Q and X are as defined.

[0573] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5At least one of the C substituted with 1 to 5 identical or different substituents n is cycloalkyl, C n The cycloalkyl group has n of 1 to 10, and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2 independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0574] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the n Heterocycloalkyl, C n n of heterocycloalkyl is 1 to 10, and R 1 , R 6 ~R 9, Q and X are as defined.

[0575] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of n Heterocycloalkyl, C n n of heterocycloalkyl is 1 to 10, and R 1 , R 6 ~R 9 , Q and X are as defined.

[0576] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n Heterocycloalkyl, C n Heterocycloalkyl n is 1 to 10, and each substituent is H, 2 H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0577]

[0013] Embodiments of the present invention include compounds of formula (II), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituentsn Heterocycloalkyl, C n Heterocycloalkyl n is 1 to 10 and at least one substituent is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and R 1 , R 6 ~R 9 , Q and X are as defined.

[0578] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected and R 2 ~R 5 At least one of the C substituted with 1 to 5 identical or different substituents n Heterocycloalkyl, C n Heterocycloalkyl n is 1 to 10 and at least one of the substituents is -C q -UC q and -C q -UC q Each q is independently 0 to 10; q -UC q U is N(R1)(R1), and each R1 in N(R1)(R1) is independently hydrogen, C n Alkyl, C n Alkenyl, C n alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein each R1 in N(R1)(R1) is substituted with 1 to 5 substituents, and the substituents of each R1 in N(R1)(R1) are the same or different and are H, 2independently selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 1 , R 6 ~R 9 , Q and X are as defined.

[0579] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Q is a bond, and R 1 ~R 9 and X is as defined.

[0580] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, Q is O, and R 1 ~R 9 and X is as defined.

[0581] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, X is C, and R 1 ~R 9 and X is as defined.

[0582] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, X is N, and R 1 ~R 9 , R 1 ~R 9 and X is as defined.

[0583] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, X is O, and R 6 does not exist, and R 1 ~R 5 , R 7 ~R 9 , R 1 ~R 9 and X is as defined. One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, X is S, and R 6 does not exist, and R 1 ~R 5 , R 7 ~R 9 , R 1 ~R 9 and X is as defined.

[0584] One embodiment of the present invention includes a compound of formula (II), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 to 3, and R 1 ~R 9 , Q and X are as defined.

[0585] Formula III A further embodiment of the present invention is a compound of formula III [ka] or a pharmaceutically acceptable salt or ester thereof, R 1 is -CN, alkyl, -H, halo, 2selected from the group consisting of H, amino, alkoxy, aminoalkyl, (amino)alkoxy, alkenyl, alkynyl, alkoxy, hydroxy, alkylhydroxy, aryloxy, alkyl(aryl), (alkoxyalkyl)amino, aryl, aryl(halo), heteroaryl, hydroxyl-alkyl, hydroxyl-aryl, (aryl)alkyl, C(O)OH, —S(O)2-alkyl, —S(O)2-aryl, —C(O)alkyl, and C(O)NH2; R 3 and R 4 each independently represents -H, halo, C n Alkyl, C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, C n Heterocycloalkyl and -C q -UC q and n is 1 to 10, -C q -UC q Each q is independently 0 to 10; -C q -UC q U is any one of O, S, SO2, or N(R1)(R1), each R in N(R)(R) is independently hydrogen; C n Alkyl, C n Alkenyl, C n Alkynyl, C n Aryl, C n Aminoalkyl, C n Haloalkyl, C n Heteroaryl, C n Cycloalkyl, or C n each heterocycloalkyl is unsubstituted or substituted with 1 to 5 substituents; each substituent is the same or different; Each substituent is H, 2 selected from the group consisting of H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl and -C(O)alkyl; R 6 are independently H or alkyl; R 7 and R 8 each independently represents hydrogen, 2 H, fluoro or alkyl; R 6 and R 7 combines with an adjacent R group to form a fused group, the fused group is selected from the group consisting of fused cycloalkyl, fused heterocycloalkyl, fused aryl, and fused heteroaryl rings; The fused group contains 4 to 10 carbon atoms, n in formula III is 0 or 1; Q is a bond or O; If X is O or S, then R 6 X is C, N, O or S, so that Z 1 or W 1 is independently C, N, O or S.

[0586] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0, and R 1 , R 3 ~R 4 , R 6 ~R 8 , Q, X, Z 1 and W 1is as defined.

[0587] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 1, and R 1 , R 3 ~R 4 , R 6 ~R 8 , Q, X, Z 1 and W 1 is as defined.

[0588] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, Q is a bond, and R 1 , R 3 ~R 4 , R 6 ~R 8 , X, Z 1 and W 1 is as defined.

[0589] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, Q is O, and R 1 , R 3 ~R 4 , R 6 ~R 8 , X, Z 1 and W 1 is as defined.

[0590] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, X is C, and R 1 , R 3 ~R 4 , R 6 ~R 8 , Q, Z 1 and W 1 is as defined.

[0591] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, X is N, and R 1 , R 3 ~R 4 , R 6 ~R 8 , Q, Z 1 and W 1 is as defined.

[0592] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, X is O, and R 6 does not exist, and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, Z 1 and W 1 is as defined.

[0593] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, X is S, and R 6 does not exist, and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, Z 1 and W 1 is as defined.

[0594] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, and Z 1 is C and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, X and W 1 is as defined.

[0595] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, and Z 1 is N and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, X and W 1 is as defined.

[0596] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, and Z 1 is O and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, X and W 1 is as defined.

[0597] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, and Z 1 is S and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, X and W 1 is as defined.

[0598]

[0013] Embodiments of the present invention include compounds of formula (III), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected, n is 0 or 1, and W 1 is C and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, X and Z 1 is as defined.

[0599]

[0013] Embodiments of the present invention include compounds of formula (III), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected, n is 0 or 1, and W 1 is N and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, X and Z 1 is as defined.

[0600]

[0013] Embodiments of the present invention include compounds of formula (III), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected, n is 0 or 1, and W 1 is O and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, X and Z 1 is as defined.

[0601]

[0013] Embodiments of the present invention include compounds of formula (III), or pharmaceutically acceptable salts or esters thereof, wherein the various moieties are independently selected, n is 0 or 1, and W 1 is S and R 1 , R 3 ~R 4 , R 7 ~R 8 , Q, X and Z 1 is as defined.

[0602] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, and R 1 is -CN and R 3 ~R 4 , R 6 ~R 8 , Q, X, Z 1 and W 1 is as defined.

[0603] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, and R 1 is alkyl, and R 3 ~R 4 , R 6 ~R 8 , Q, X, Z 1 and W 1 is as defined.

[0604] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the various moieties are independently selected, n is 0 or 1, and R 1 is -H and R 3 ~R 4 , R 6 ~R 8 , Q, X, Z 1 and W 1 is as defined.

[0605] One embodiment of the present invention includes a compound of formula (III), or a pharmaceutically acceptable salt or ester thereof, wherein the variou...

Claims

【Request Item 1】 【Chemistry 1】 A compound of formula I or a pharmaceutically acceptable salt thereof (In the formula, R １ is selected from the group consisting of fluorophenyl, morpholinyl, pyridyl, hydrogen, halo, benzoic acid, difluoropiperidinyl, difluoropyrrolidinyl, methylpyridinyl, dimethyloxazolyl, cyanophenyl, phenyl, hydroxyphenyl, methylphenyl, and carbamoylphenyl; R ２ is hydrogen, R ３ is selected from the group consisting of hydrogen, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, fluorophenyl, pentanamido, pentyloxy, bromo, hex-1-enyl, phenylethylene, propylphenyl, phenylpropyl, benzyloxy, methoxy, methylphenylethylene, pyridine-ethyl, chlorophenylethylene, morpholine-ethylene, methylpiperazine-ethylene, methoxyphenylethylene, phenyl, pyrazine-ethylene, pyrimidine-ethylene, quinoxaline-ethylene, tetrahydroquinoxaline-ethylene, quinoline-ethylene, tetrahydroquinoline-ethylene, pyrrolopyridine-ethylene, benzothiazole-ethylene, benzoxazole-ethylene, benzodiazole-ethylene, methylbenzodiazole-ethylene, methylphenylamino-ethylene, tetrahydroisoquinoline-ethylene, dihydroindole-ethylene, hydroxypiperidine-ethylene, pyrrolidine-ethylene, diethylaminoethyl, and dihydroisoindole-ethylene; R ４ is selected from the group consisting of hydrogen, bromo, and hexyl; R ５ is hydrogen, R ６ is selected from the group consisting of hydrogen, methyl, ethyl, and cyclopropyl; R ７ , R ８ , and / or R ９ are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, formic acid, ethanoic acid, propanoic acid, butanoic acid, isopropyl, 2-methylpropyl, 2-methylpropanoic acid, methylamino-acetamido-acetic acid, tetrazolyl, 1,3-thiazolidine-2,4-dione, and hydroxyethyl-acetamidyl, wherein R ７ , R ８ , and / or R ９ At least one of the is not hydrogen, Here, R ７ , R ８ , or R ９ Together with R ６ may form a ring to form a member selected from the group consisting of piperidinyl, morpholinyl, pyrrolidinyl, azetidinyl, cyclopropyl, oxopyrrolidinyl, imidazolyl, pyrrolyl, methylpyrrolidinyl, and 5-oxopyrrolidinyl; Q is a bond or O; X is CH or R ６ When X forms an aromatic ring with the adjacent R group, it is C, or N, or O, provided that when X is O, R ６ does not exist, "A" is 【Chemistry 2】 and Y, T, W and Z are independently C; and n is 0, 1, 2, or 3.

2. R ６ , and R ７ , R ８ and R ９ The compound of claim 1 , wherein one of:

3. R ３ is C ｎ The compound of claim 1, wherein n is alkyl and n is 3 to 7.

4. R １ The compound of claim 1 , wherein is halo.

5. 2. The compound of claim 1, wherein Q is a bond.

6. 3-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 3-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{[4-(4-fluorophenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-3-methyl-4-(morpholin-4-yl)quinolin-2-yl 1](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexyl-3-methylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4,6-bis(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](2-methylpropyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](propyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](propyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl yl]amino}acetic acid, 2-{ethyl[4-(4-fluorophenyl)-6-hexylquinolin-2-yl]amino}acetic acid, 2-{[6-hexyl-4-(pyridin-3-yloxy)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(pyridin-4-yloxy)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-fluorophenoxy)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenoxy)-6-hexylquinolin-2-yl](methyl)amino}acetic acid no}acetic acid, 2-{[4-(4-fluorophenyl)-6-octylquinolin-2-yl](2-methylpropyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-octylquinolin-2-yl](propyl)amino}acetic acid, 2-{ethyl[4-(4-fluorophenyl)-6-octylquinolin-2-yl]amino}acetic acid, 2-{methyl[6-octyl-4-(pyridin-3-yloxy)quinolin-2-yl]amino}acetic acid, 2-{methyl[6-octyl-4-(pyridin-4-yloxy)quinolin-2-yl]amino}acetic acid,2-{[4-(3-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-decyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-heptylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-[(6-hexyl 2-{2-[(carboxymethyl)(methyl)amino]-6-hexylquinolin-4-yl}benzoic acid, 2-{[4-(4,4-difluoropiperidin-1-yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3,3-difluoropyrrolidin-1-yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(morpholin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2- 2-{[4-(3,5-dimethyl-1,2-oxazol-4-yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 3-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}butanoic acid, 3-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 2-[methyl methyl(6-pentanamido-4-phenylquinolin-2-yl)amino]acetic acid, 2-{methyl[6-(pentyloxy)-4-phenylquinolin-2-yl]amino}acetic acid, 2-[(7-bromo-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[(7-hexyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[methyl(6-octyl-4-phenylquinolin-2-yl)amino]acetic acid, 3-{[6-hexyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid,2-{[6-hexyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl]oxy}acetic acid, 3-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 1-[6-hexyl-4-(pyridin-3-yl)quinolin-2-yl]piperidine-3-carboxylic acid, 1-(6-hexyl-4-phenyl) 2-{[6-butyl-4-(4-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid butyl)amino}acetic acid, 2-{[6-butyl-4-(2-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(4-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(4-cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-( 4-carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(pyridin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 6-butyl-2-(carboxymethoxy)-4-phenylquinoline-3-carboxylic acid, 2-{[6-butyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}acetic acid, 1-[6-butyl-4-(3-cyanophenyl)quinolin-2-yl]piperidine-3-carboxylic acid, 4-(6-butyl-4-phenylquinolin-2-yl)morpholine-2-carboxylic acid,1-(6-butyl-4-phenylquinolin-2-yl)piperidine-3-carboxylic acid, 3-{[6-butyl-(4-(3-cyanophenyl)quinolin-2-yl)(methyl)amino}-2-methylpropanoic acid, 3-{[6-butyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 3-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 3-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]butanoic acid, 3-[(6-butyl- 4-phenylquinolin-2-yl)(methyl)amino]propanoic acid, N-(6-butyl-4-(3-cyanophenyl)quinolin-2-yl)-N-methylvaline, 2-{[4-(3-cyanophenyl)-6-pentylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-pentylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3-cyanophenyl)-6-propylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-propylquinolin-2-yl]oxy}acetic acid, 2- {[4-(3-carbamoylphenyl)-6-ethylquinolin-2-yl]oxy}acetic acid, 2-{[6-bromo-4-(3-cyanophenyl)quinolin-2-yl]oxy}acetic acid, 2-{[6-bromo-4-(3-carbamoylphenyl)quinolin-2-yl]oxy}acetic acid, 2-{[6-butyl-4-(3-cyanophenyl)quinolin-2-yl]oxy}acetic acid, 2-{[6-butyl-4-(3-carbamoylphenyl)quinolin-2-yl]oxy}acetic acid, 2-{[4-(3-cyanophenyl)-6-pentylquinolin-2-yl](methyl ) amino}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6-ethylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-ethylquinolin-2-yl](methyl)amino}acetic acid,2-{[6-bromo-4-(3-cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-bromo-4-(3-carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{2-[(6-chloro-4-phenylquinolin-2-yl)(methyl)amino]acetamido}acetic acid, 2-[methyl ethyl(6-pentyl-4-phenylquinolin-2-yl)amino]acetic acid, 2-[methyl(4-phenyl-6-propylquinolin-2-yl)amino]acetic acid, 2-[(6-ethyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 1-(6-hexyl-4-phenylquinolin-2-yl)pyrrolidine-2-carboxylic acid, 6-hexyl-4-phenyl-2-(piperidin-1-yl)quinoline, 2-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 1-(6-butyl-4-phenylquinoline -2-yl)pyrrolidine-2-carboxylic acid, 6-butyl-4-phenyl-2-(piperidin-1-yl)quinoline, 2-[(6-bromo-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-bromo-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[(6-pentyl-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(4-phenyl-6-propylquinolin-2-yl)oxy]acetic acid, 2-[(6-ethyl-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-chloro-4-phenyl 1-(6-chloro-4-phenylquinolin-2-yl)pyrrolidine-2-carboxylic acid, 2-[(6-chloro-4-phenylquinolin-2-yl)(methyl)amino]propanoic acid, 2-[(6-chloro-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 6-chloro-4-phenyl-2-(piperidin-1-yl)quinoline,3-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-[methyl(6-octyl-4-phenylquinolin-2-yl)amino]acetic acid, 2-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{methyl[6-octyl-4-(pyridin-3-yloxy)quinolin-2-yl]amino}acetic acid, 2-{[6-butyl-4-(3-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-[, (6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-{[4-(4-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-{[6-decyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-[methyl(4-phenyl-6-propylquinolin-2-yl) phenyl)amino]acetic acid, 2-{[6-butyl-4-(4-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 3-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 2-{[4-(4-fluorophenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, [6-hexyl-4-(pyridin-3-yloxy)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-[methyl(6-pentyl-4-phenylquinolin-2-yl)amino]acetic acid, 3-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 2-{[4-(3-cyanophenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(mol 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 3-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 3-{[4-(3-cyanophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-[methyl({6-[2-(4-methylphenyl)ethyl]-4-phenylquinolin-2-yl})amino]acetic acid,2-[methyl({6-[2-(3-methylphenyl)ethyl]-4-phenylquinolin-2-yl})amino]acetic acid, 6-hexyl-N-methyl-4-phenyl-N-[(2H-1,2,3,4-tetrazol-5-yl)methyl]quinolin-2-amine, 2-{methyl[4-phenyl-6-(2-phenylethyl)quinolin-2-yl]amino}acetic acid, 2-({6-[2-(3-chlorophenyl)ethyl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 5-{[4-phenyl-6-(2-phenylethyl)quinolin-2-yl phenyl]methyl}-1,3-thiazolidine-2,4-dione, 2-({6-[2-(4-chlorophenyl)ethyl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-[methyl({4-phenyl-6-[2-(pyridin-3-yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-[methyl({4-phenyl-6-[2-(quinolin-6-yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-[(6-heptyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[methyl({6-[2-(2-methylphenyl)ethyl]quinolin-2-yl})amino]acetic acid 1-(6-hexyl-4-phenylquinolin-2-yl)-3-methylpyrrolidine-3-carboxylic acid, 2-[methyl({4-phenyl-6-[2-(pyrimidin-2-yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-[methyl({4-phenyl-6-[2-(pyridin-2-yl)ethyl]quinolin-2-yl})amino]acetic acid, cis-2-(6-hexyl-4-phenylquinolin-2-yl)cyclopropane-1-carboxylic acid, 1-(6-hexyl-4-phenylquinolin-2-yl)-3-methylpyrrolidine-3-carboxylic acid, 2-[methyl({4-phenyl-6-[2-(pyrimidin-2-yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-[(6-hexyl-4-phenyl 2-[methyl({4-phenyl-6-[2-(quinoxalin-6-yl)ethyl]quinolin-2-yl})amino]acetic acid, 5-[(6-hexyl-4-phenylquinolin-2-yl)methyl]-1,3-thiazolidine-2,4-dione, 2-({6-[(1E)-hex-1-en-1-yl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-{methyl[4-phenyl-6-(3-phenylpropyl)quinolin-2-yl]amino}acetic acid,A compound selected from the group consisting of 2-[methyl({4-phenyl-6-[2-(1,2,3,4-tetrahydroquinolin-6-yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-({6-[2-(3-methoxyphenyl)ethyl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-({6-[2-(1,3-benzothiazol-2-yl)ethyl]-4-phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-{[6-hexyl-4-(pyridin-4-yl)quinolin-2-yl]oxy}propanoic acid, and 3-(6-hexyl-4-phenylquinolin-2-yl)butanoic acid.

7. 10. A pharmaceutical composition for inhibiting fatty acid binding protein FABP4 in a mammal, comprising an effective amount of a compound of claim 1.

8. The pharmaceutical composition of claim 7 , wherein the subject is a human.

9. 10. A pharmaceutical composition comprising a compound according to claim 1 for use in the prevention or treatment of disorders affecting the fatty acid binding protein FABP4.

10. 10. The pharmaceutical composition of claim 9, wherein the disorder is selected from type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, intracranial atherosclerotic disease, non-alcoholic steatohepatitis, asthma, multiple sclerosis, Alzheimer's disease, other chronic inflammatory and autoimmune / inflammatory diseases, chronic heart disease, polycystic ovary syndrome, pre-eclampsia (preeclampsia), and cancer.

11. 11. The pharmaceutical composition of claim 10, further comprising at least one additional active ingredient or pharmaceutically acceptable carrier.

12. 10. Use of a compound of claim 1 for the preparation of a medicament for preventing or treating a disorder affecting the fatty acid binding protein FABP4, comprising administering to a subject in need of such treatment an effective amount of a compound of claim 1, wherein the disorder is selected from the group consisting of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, intracranial atherosclerotic disease, and non-alcoholic steatohepatitis.

13. The use according to claim 12, wherein the subject is a human.

14. Use of a compound described in claim 6 for preparing a medicament for inhibiting fatty acid binding protein FABP4 in a mammal, comprising administering to the mammal an effective amount of a compound described in claim 1, wherein the disorder related to the inhibition of fatty acid binding protein FABP4 is selected from the group consisting of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, arteriosclerosis, intracranial atherosclerotic disease, and non-alcoholic steatohepatitis.

15. The use according to claim 14, wherein the subject is a human.

16. 10. Use of a compound according to claim 6 for the preparation of a medicament for the prevention or treatment of a disease acting on the fatty acid binding protein FABP4, wherein the disorder is selected from the group consisting of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, arteriosclerosis, intracranial arteriosclerotic disease, and non-alcoholic steatohepatitis.

17. A pharmaceutical composition comprising the compound of claim 6 as an active ingredient.

18. 18. The pharmaceutical composition of claim 17, further comprising at least one additional active ingredient or a pharmaceutically acceptable carrier.

19. 10. Use of a compound according to claim 6 for the preparation of a medicament for the prevention or treatment of a disease acting on the fatty acid binding protein FABP4, comprising administering to a subject in need of such treatment an effective amount of a compound according to claim 1, wherein the disorder is selected from the group consisting of type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, arteriosclerosis, intracranial arteriosclerotic disease, and non-alcoholic steatohepatitis.

20. 20. The use according to claim 19, wherein the subject is a human.

Images